Advertisement

Multiple Bacteriophage Selection Strategies for Improved Affinity of a Peptide Targeting ERBB2

  • Benjamin M. Larimer
  • Jeanne M. Quinn
  • Kevin Kramer
  • Andrey Komissarov
  • Susan L. Deutscher
Article

Abstract

Due to the heterogeneity of ERBB2-expression between tumors and over the course of treatment, a non-invasive molecular imaging agent is needed to accurately detect overall ERBB2 status. Peptides are a highly advantageous platform for molecular imaging, since they have excellent tumor penetration and rapid pharmacokinetics. One limitation of peptides however, is their traditionally low target affinity, and consequently, tumor uptake. The peptide KCCYSL was previously selected from a bacteriophage (phage) display library to bind ERBB2 and did so with moderate affinity of 295 nM. In order to enhance tumor uptake and clinical utility of the peptide, a novel phage microlibrary was created by flanking the parent sequence with random amino acids, followed by reselection using parallel strategies for high affinity and specific ERBB2 binding in an attempt to affinity maturate the peptide. One limitation of traditional phage display selections is difficulty in releasing the highest affinity phages from the target by incubation of acidic buffer. In an attempt to recover high affinity second-generation peptides from the ERBB2 microlibrary, two elution strategies, sonication and target elution, were undertaken. Sonication resulted in an approximately 50-fold enhancement in recovered phage per round of selection in comparison to target elution. Despite the differences in elution efficiency, the affinities of phage-displayed peptides selected from either strategy were relatively similar. Although both selections yielded peptides with significantly improved affinity in comparison to KCCYSL, the improvements were modest, most likely because the parental peptide binding cannot be improved by additional amino acids.

Keywords

Affinity maturation ERBB2 Peptides Phage display 

Abbreviations

ELISA

Enzyme linked immunosorbant assay

FMOC

Fluorenylmethyloxycarbonyl

GSG

Gly-Ser-Gly

KD

Dissociation constant

TBS

Tris buffered saline

TBST

Tris buffered saline and tween

TU

Tetracycline transducing units

Notes

Acknowledgments

The authors would like to thank Marie Dickerson, Jessica Newton-Northup and Fabio Gallazzi for their technical assistance. This work is supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, Clinical Sciences Research and Development including the Cooperative Studies Program, Rehabilitation Research and Development Service, and Health Services Research and Development through a VA Merit Award [I01BX000964]. Additional support provided by an National Institute of Biomedical Imaging and Bioengineering Training Grant [NIBIB 5 T32 EB004822] and an NIH R21 Grant [5R21C179069].

Conflict of interest

The authors have no conflict of interest to report.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. Baselga J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744PubMedGoogle Scholar
  2. Baselga J et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144CrossRefPubMedGoogle Scholar
  3. Binetruy-Tournaire R et al (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525–1533PubMedCentralCrossRefPubMedGoogle Scholar
  4. Cavaliere A, Sidoni A, Scheibel M, Bellezza G, Brachelente G, Vitali R, Bucciarelli E (2005) Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett 218:117–121. doi: 10.1016/j.canlet.2004.07.041 CrossRefPubMedGoogle Scholar
  5. Cho H-S, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756–760CrossRefPubMedGoogle Scholar
  6. Deutscher SL, Figueroa SD, Kumar SR (2009) 111In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas. J Labelled Comp Radiopharm 52:583–590PubMedCentralPubMedGoogle Scholar
  7. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178CrossRefPubMedGoogle Scholar
  8. Fischman AJ, Babich JW, Strauss HW (1993) A Ticket to Ride: Peptide Radiopharmaceuticals. J Nucl Med 34:2253–2263PubMedGoogle Scholar
  9. Hawkins RE, Russell SJ, Winter G (1992) Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol 226:889–896CrossRefPubMedGoogle Scholar
  10. Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP (2002) Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 21:287–296. doi: 10.1023/a:1019749504418 CrossRefPubMedGoogle Scholar
  11. Kelly KA et al (2008) Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 5:e85PubMedCentralCrossRefPubMedGoogle Scholar
  12. Koivunen E, Gay DA, Ruoslahti E (1993) Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 268:20205–20210PubMedGoogle Scholar
  13. Kumar SR, Deutscher SL (2008) 111In-Labeled Galectin-3–Targeting Peptide as a SPECT Agent for Imaging Breast Tumors. J Nucl Med 49:796–803. doi: 10.2967/jnumed.107.048751 CrossRefPubMedGoogle Scholar
  14. Kumar SR, Quinn TP, Deutscher SL (2007) Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas. Clin Cancer Res 13:6070–6079. doi: 10.1158/1078-0432.ccr-07-0160 CrossRefPubMedGoogle Scholar
  15. Kute T et al (2004) Development of Herceptin resistance in breast cancer cells. Cytometry Part A 57A:86–93. doi: 10.1002/cyto.a.10095 CrossRefGoogle Scholar
  16. Landon L, Peletskaya E, Glinsky V, Karasseva N, Quinn T, Deutscher S (2003) Combinatorial evolution of high-affinity peptides that bind to the Thomsen-Friedenreich carcinoma antigen. J Protein Chem 22:193–204. doi: 10.1023/a:1023483232397 CrossRefPubMedGoogle Scholar
  17. Landon L, Zou J, Deutscher S (2004) Effective combinatorial strategy to increase affinity of carbohydrate binding by peptides. Mol Divers 8:35–50. doi: 10.1023/b:modi.0000006897.40575.41 CrossRefPubMedGoogle Scholar
  18. Larimer B, Thomas W, Smith G, Deutscher S (2014) Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display. Mol Imaging Biol. doi: 10.1007/s11307-014-0724-5 PubMedGoogle Scholar
  19. Liu Y, Higgins CD, Overstreet CM, Rai KR, Chiorazzi N, Lai JR (2013) Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes. Mol Med 19:245PubMedCentralCrossRefPubMedGoogle Scholar
  20. Lunder M, Bratkovič T, Doljak B, Kreft S, Urleb U, Štrukelj B, Plazar N (2005) Comparison of bacterial and phage display peptide libraries in search of target-binding motif. Appl Biochem Biotechnol 127:125–131CrossRefPubMedGoogle Scholar
  21. Pande J, Szewczyk MM, Grover AK (2010) Phage display: concept, innovations, applications and future. Biotechnol Adv 28:849–858CrossRefPubMedGoogle Scholar
  22. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317CrossRefPubMedGoogle Scholar
  23. Wang Y, Wang H, Li P, Zhang Q, Kim HJ, Gee SJ, Hammock BD (2013) Phage-displayed peptide that mimics aflatoxins and its application in immunoassay. J Agric Food Chem 61:2426–2433PubMedCentralCrossRefPubMedGoogle Scholar
  24. Yu D, Hung M-C (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19:6115CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2015

Authors and Affiliations

  1. 1.Research ServiceHarry S. Truman Veterans Memorial HospitalColumbiaUSA
  2. 2.Department of BiochemistryUniversity of MissouriColumbiaUSA
  3. 3.Department of BiochemistryUniversity of Texas Health Care Center TylerTylerUSA

Personalised recommendations